Oramed Pharmaceuticals (ORMP) EBITDA (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly EBITDA came in at -$3.7 million in Q1 2026, up 18.69% YoY from -$3.1 million in Q1 2025, and up 35.49% on a QoQ basis from -$5.7 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) EBITDA (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 15 years of EBITDA data on file, last reported at -$3.7 million in Q1 2026.
- Quarterly EBITDA rose 18.69% year-over-year to -$3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.2 million (up 0.5% YoY) and the FY2025 annual result came in at -$15.1 million, down 18.05% from the prior year.
- EBITDA rose to -$3.7 million in Q1 2026, from -$5.7 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$2.4 million in Q3 2025 to a low of -$12.3 million in Q4 2022.
- A 5-year average of -$5.3 million and a median of -$3.8 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA jumped 68.55% — and 2025, when it slumped 57.77%.
- Tracing ORMP's EBITDA over 5 years: stood at -$12.3 million in 2022, then jumped by 68.55% to -$3.9 million in 2023, then gained by 7.27% to -$3.6 million in 2024, then tumbled by 57.77% to -$5.7 million in 2025, then surged by 35.49% to -$3.7 million in 2026.
- The last three EBITDA figures came in at -$3.7 million (Q1 2026), -$5.7 million (Q4 2025), and -$2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Oramed Pharmaceuticals | 196.17 Mn | 196.17 Mn | - | -2.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.77 Mn |
| Mar 31, 2026 | -3.66 Mn |
| Dec 31, 2025 | -5.67 Mn |
| Sep 30, 2025 | -2.43 Mn |
| Jun 30, 2025 | -2.49 Mn |
| Mar 31, 2025 | -4.50 Mn |
| Dec 31, 2024 | -3.60 Mn |
| Sep 30, 2024 | -3.09 Mn |
| Jun 30, 2024 | -3.14 Mn |
| Mar 31, 2024 | -2.96 Mn |
| Dec 31, 2023 | -3.88 Mn |
| Sep 30, 2023 | -2.89 Mn |
| Jun 30, 2023 | -3.79 Mn |
| Mar 31, 2023 | -5.21 Mn |
| Dec 31, 2022 | -12.33 Mn |
| Sep 30, 2022 | -8.19 Mn |
| Jun 30, 2022 | -11.42 Mn |
| Mar 31, 2022 | -11.25 Mn |
| Aug 31, 2021 | -24.22 Mn |
| Nov 30, 2019 | -2.43 Mn |